carboplatin + pemetrexed + sorafenib

The combination of carboplatin, pemetrexed, and sorafenib is a multi-drug regimen that has been investigated in clinical trials for various cancer types. This combination brings together different mechanisms of action to potentially enhance anti-cancer effects. ## Description Carboplatin + pemetrexed + sorafenib is a combination therapy that has been studied in phase I clinical trials for the treatment of various cancers, particularly non-small cell lung cancer (NSCLC). The combination incorporates: - **Carboplatin**: An alkylating agent that forms DNA crosslinks, inhibiting DNA synthesis and function - **Pemetrexed**: An antifolate antimetabolite that inhibits multiple enzymes in the folate pathway - **Sorafenib**: A multi-kinase inhibitor targeting Raf kinases and several receptor tyrosine kinases Clinical trials have established that the maximum tolerated dose (MTD) of sorafenib in this combination is 200 mg twice daily when used with carboplatin (AUC=5) and pemetrexed 500 mg/m² administered every 3 weeks[6]. Higher doses of sorafenib (400 mg twice daily) with this combination resulted in excessive toxicity[1][5]. ## Clinical Development Phase I trials have shown that this combination has significant toxicity concerns, particularly thrombocytopenia. The combination of sorafenib with carboplatin and pemetrexed resulted in unexpectedly severe thrombocytopenia, possibly due to synergistic effects on platelets[1]. Platelets and megakaryocytes express VEGFRs, which are targeted by sorafenib, potentially explaining the enhanced platelet toxicity when combined with carboplatin's direct platelet toxicity[1]. Other common toxicities observed included neutropenia, fatigue, anorexia, and skin reactions[5][6]. Some patients required dose reductions due to these adverse effects[5]. Response rates in clinical trials included partial responses in some patients, particularly in non-small cell lung cancer[6]. However, the high toxicity profile has raised questions about the clinical utility of this specific three-drug combination[1][5]. ## Dosing and Administration In clinical trials, the regimen was typically administered as follows: - Pemetrexed: 500 mg/m² intravenously on day 1 of a 3-week cycle - Carboplatin: AUC=5 intravenously on day 1 of a 3-week cycle - Sorafenib: 200 mg orally twice daily continuously Patients also received supplementation with folic acid and vitamin B12 to reduce pemetrexed-related toxicities, as well as steroid premedication[4][5]. The maximum tolerated dose of sorafenib in this combination was determined to be 200 mg twice daily, with higher doses resulting in unacceptable toxicity[1][6].